Kathrin Jobski1,2, Niklas Schmedt3, Bianca Kollhorst3, Jutta Krappweis4, Tania Schink3, Edeltraut Garbe3,5. 1. Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany. kathrin.jobski@uni-oldenburg.de. 2. Department of Health Services Research, Carl von Ossietzky University Oldenburg, Ammerländer Heerstrasse 140, 26111, Oldenburg, Germany. kathrin.jobski@uni-oldenburg.de. 3. Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany. 4. Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany. 5. Core Scientific Area Health Sciences, University of Bremen, Bremen, Germany.
Abstract
PURPOSE: The purpose of this study was to investigate characteristics, drug use patterns, and predictors for treatment choice in older German patients initiating antidepressant (AD) treatment. METHODS: Using the German Pharmacoepidemiological Research Database, we identified a cohort of AD initiators aged at least 65 years between 2005 and 2011. Potential indications, co-morbidity, and co-medication as well as treatment patterns such as the duration of the first treatment episode were assessed. In addition, a logistic regression model was used to identify independent predictors for initiating treatment with tricyclic ADs (TCAs) compared to selective serotonin reuptake inhibitors (SSRIs). RESULTS: Overall, 508,810 individuals were included in the cohort. About 55 % of patients initiated AD treatment with TCAs, followed by 22 % receiving SSRIs. During the study period, a decrease of treatment initiation with TCAs was observed. Higher age and male sex as well as being diagnosed with depression were highly associated with SSRI treatment, whereas pain and sleeping disorders were strong predictors for initiating TCA treatment. The duration of the first treatment episode was substantially longer in SSRI users compared to TCA initiators (median 119 vs. 43 days). CONCLUSIONS: Potential indications and drug use patterns in older German AD initiators varied substantially for different drug classes and single agents. Given the anticholinergic and sedative properties of TCAs, the frequent use of this drug class though probably related to indications such as pain was remarkable.
PURPOSE: The purpose of this study was to investigate characteristics, drug use patterns, and predictors for treatment choice in older German patients initiating antidepressant (AD) treatment. METHODS: Using the German Pharmacoepidemiological Research Database, we identified a cohort of AD initiators aged at least 65 years between 2005 and 2011. Potential indications, co-morbidity, and co-medication as well as treatment patterns such as the duration of the first treatment episode were assessed. In addition, a logistic regression model was used to identify independent predictors for initiating treatment with tricyclic ADs (TCAs) compared to selective serotonin reuptake inhibitors (SSRIs). RESULTS: Overall, 508,810 individuals were included in the cohort. About 55 % of patients initiated AD treatment with TCAs, followed by 22 % receiving SSRIs. During the study period, a decrease of treatment initiation with TCAs was observed. Higher age and male sex as well as being diagnosed with depression were highly associated with SSRI treatment, whereas pain and sleeping disorders were strong predictors for initiating TCA treatment. The duration of the first treatment episode was substantially longer in SSRI users compared to TCA initiators (median 119 vs. 43 days). CONCLUSIONS: Potential indications and drug use patterns in older German AD initiators varied substantially for different drug classes and single agents. Given the anticholinergic and sedative properties of TCAs, the frequent use of this drug class though probably related to indications such as pain was remarkable.
Entities:
Keywords:
Antidepressants; Drug utilization; Germany; Older patients; Tricyclic antidepressants
Authors: R A Greevy; M M Huizinga; C L Roumie; C G Grijalva; H Murff; X Liu; M R Griffin Journal: Clin Pharmacol Ther Date: 2011-11-02 Impact factor: 6.875
Authors: Raymond Noordam; Nikkie Aarts; Katia M Verhamme; Miriam C M Sturkenboom; Bruno H Stricker; Loes E Visser Journal: Eur J Clin Pharmacol Date: 2015-01-06 Impact factor: 2.953
Authors: V Abbing-Karahagopian; C Huerta; P C Souverein; F de Abajo; H G M Leufkens; J Slattery; Y Alvarez; M Miret; M Gil; B Oliva; U Hesse; G Requena; F de Vries; M Rottenkolber; S Schmiedl; R Reynolds; R G Schlienger; M C H de Groot; O H Klungel; T P van Staa; L van Dijk; A C G Egberts; H Gardarsdottir; M L De Bruin Journal: Eur J Clin Pharmacol Date: 2014-05-03 Impact factor: 2.953
Authors: Manel Pladevall-Vila; Anton Pottegård; Tania Schink; Johan Reutfors; Rosa Morros; Beatriz Poblador-Plou; Antje Timmer; Joan Forns; Maja Hellfritzsch; Tammo Reinders; David Hägg; Maria Giner-Soriano; Alexandra Prados-Torres; Miguel Cainzos-Achirica; Jesper Hallas; Lena Brandt; Jordi Cortés; Jaume Aguado; Gabriel Perlemuter; Bruno Falissard; Jordi Castellsagué; Emmanuelle Jacquot; Nicolas Deltour; Susana Perez-Gutthann Journal: CNS Drugs Date: 2019-04 Impact factor: 5.749
Authors: Joan Forns; Miguel Cainzos-Achirica; Maja Hellfritzsch; Rosa Morros; Beatriz Poblador-Plou; Jesper Hallas; Maria Giner-Soriano; Alexandra Prados-Torres; Anton Pottegård; Jordi Cortés; Jordi Castellsagué; Emmanuelle Jacquot; Nicolas Deltour; Susana Perez-Gutthann; Manel Pladevall Journal: Pharmacoepidemiol Drug Saf Date: 2019-06-06 Impact factor: 2.890
Authors: Philipp Hessmann; Jan Zeidler; Jona Stahmeyer; Sveja Eberhard; Jonathan Vogelgsang; Mona Abdel-Hamid; Claus Wolff-Menzler; Jens Wiltfang; Bernhard Kis Journal: Front Pharmacol Date: 2019-07-24 Impact factor: 5.810